The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats  by Lopez, I. et al.
The effect of calcitriol, paricalcitol, and a calcimimetic
on extraosseous calcifications in uremic rats
I Lopez1, FJ Mendoza1, E Aguilera-Tejero1, J Perez2, F Guerrero1, D Martin3 and M Rodriguez4
1Department of Medicina y Cirugia Animal, Universidad de Cordoba, Cordoba, Spain; 2Department of Anatomia y Anatomia Patologica
Comparadas, Universidad de Cordoba, Cordoba, Spain; 3Department of Metabolic Disorders, Amgen Inc, Thousand Oaks, California,
USA and 4Unidad de Investigacion y Servicio de Nefrologia, Hospital Universitario Reina Sofia, Cordoba, Spain
Vitamin D derivatives and calcimimetics are used to treat
secondary hyperparathyroidism in patients with chronic
renal failure. We investigated the effect of calcitriol,
paricalcitol, and the calcimimetic AMG 641 on soft-tissue
calcification in uremic rats with secondary
hyperparathyroidism. Control and uremic rats were treated
with vehicle, calcitriol, paricalcitol, AMG 641, or a
combination of AMG 641 plus calcitriol or paricalcitol.
Parathyroid hormone levels were reduced by all treatments
but were better controlled by the combination of paricalcitol
and AMG 641. The calcimimetic alone did not induce
extraosseous calcification but co-administration of AMG 641
reduced soft-tissue calcification and aortic mineralization in
both calcitriol- and paricalcitol-treated rats. Survival was
significantly reduced in rats treated with calcitriol and this
mortality was attenuated by co-treatment with AMG 641.
Our study shows that extraskeletal calcification was present
in animals treated with calcitriol and paricalcitol but not with
AMG 641. When used in combination with paricalcitol, AMG
641 provided excellent control of secondary
hyperparathyroidism and prevented mortality associated
with the use of vitamin D derivatives without causing tissue
calcification.
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Secondary hyperparathyroidism (HPT) and vascular calcifi-
cation (VC) are common complications of stage 5 chronic
kidney disease. The elevations in calcium, phosphorus, and
Ca P product observed in patients with secondary HPT
have been associated with VC and increased risk of
cardiovascular morbidity and mortality.1–4
Vitamin D derivatives, such as calcitriol and paricalcitol,
are commonly used to treat the elevated parathyroid
hormone (PTH) associated with secondary HPT;5–10 how-
ever, they have been shown to induce VC in vivo and in vitro
animal models.11–13 Vitamin D derivatives increase expres-
sion of several proteins involved in calcification and decrease
expression of proteins that inhibit calcification.14,15 In
addition, they potentially lead to hypercalcemia and
hyperphosphatemia,6,7,10 although paricalcitol has been
reported to have less calcemic effects than calcitriol.16,17
Together, these data suggest the need for alternative treatment
strategies.
One such strategy is the use of calcimimetics. These
compounds bind to the calcium-sensing receptor and
increase its sensitivity to extracellular calcium, thereby
suppressing PTH synthesis18 and secretion19 without indu-
cing hypercalcemia.20,21 We have recently demonstrated that,
when administered to uremic rats, the calcimimetic R-568
reduces PTH levels without inducing VC, attenuates the
calcitriol-induced calcifying effects on vascular tissue, and
decreases mortality associated with calcitriol.22 AMG 641 is a
research calcimimetic that has a more sustained action than
R-568, allowing administration every 48 h.
In this study, we investigate the effect of calcitriol,
paricalcitol, and the research calcimimetic AMG 641, alone
or in combination, on the development of vascular and other
soft-tissue calcifications in a rat model of uremia-associated
secondary HPT.
RESULTS
Animal survival
During the first 14 days following nephrectomy and the
change in diet, survival was 490% in all treatment groups,
except in rats treated with calcitriol, in which survival was
80%. However, marked differences in survival were found
between treatment groups from days 15 through 28. Survival
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was not different in the five-sixth (5/6) Nxþ vehicle (100%)
and in the AMG 641 groups (86%). However, treatment with
vitamin D derivatives resulted in a significant reduction in
survival that was more marked with calcitriol (18%, Po0.001
vs 5/6 Nxþ vehicle) than with paricalcitol (50%, P¼ 0.02 vs
5/6 Nxþ vehicle). The addition of AMG 641 to the vitamin
D derivatives improved survival both in calcitriol (40%)- and
in paricalcitol (70%, NS vs 5/6 Nxþ vehicle)-treated rats
(Figure 1).
Serum biochemical parameters
At day 14, mean plasma creatinine concentration in sham-
operated rats was 0.57±0.01 mg per 100 ml. As expected, all
5/6 Nx rats had significantly (Po0.05) higher creatinine
levels, but significant differences were found between
treatment groups. Plasma creatinine concentrations in rats
treated with either calcitriol (1.86±0.68 mg per 100 ml) or
paricalcitol (1.83±0.85 mg per 100 ml) were significantly
higher (Po0.05) than in rats treated with vehicle
(1.16±0.05 mg per 100 ml) or AMG 641 (0.94±0.14 mg
per 100 ml). Addition of AMG 641 to vitamin D derivatives
significantly (P¼ 0.001) reduced plasma creatinine in
paricalcitol-treated rats (1.15±0.27 mg per 100 ml) but not
in rats treated with calcitriol (1.58±0.51 mg per 100 ml).
Plasma levels of ionized calcium, phosphorus, and PTH at
day 14 are depicted in Figure 2. Plasma ionized calcium levels
were significantly (Po0.001) reduced in all 5/6 Nx groups
(range 0.92–1.05 mmol l1) when compared with sham-
operated rats (1.18±0.02 mmol l1). A higher ionized
calcium concentration (Po0.05) was identified in rats
treated with calcitriol (1.05±0.03 mmol l1) than in groups
treated with AMG 641 (0.94±0.02 mmol l1) and paricalcitol
(0.92±0.03 mmol l1) (Figure 2a). Plasma phosphorus levels
(Figure 2b) were consistently (Po0.01) elevated in 5/6 Nx
rats, except in groups treated with AMG 641. Plasma
phosphorus was higher in rats treated with calcitriol
(19.7±1.6 mg per 100 ml), and lower in rats treated with
AMG 641 alone (9.1±0.7 mg per 100 ml). Paricalcitol treated
rats had significantly higher (P¼ 0.002) plasma phosphorus
(16.0±2.1 mg per 100 ml) than rats treated with AMG 641
(9.1±0.7 mg per 100 ml). It is also interesting to note that
addition of AMG 641 achieved a reduction in plasma
phosphorus both in rats treated with paricalcitol
(10.2±0.8 mg per 100 ml) and in rats treated with calcitriol
(14.8±1.8 mg per 100 ml). Plasma PTH concentration was
significantly (Po0.001) increased in 5/6 Nx rats
(450.1±45.9 pg ml1) when compared with sham-operated
animals (44.4±16.2 pg ml1). Treatment with AMG 641,
alone or in combination with vitamin D derivatives, reduced
plasma PTH concentrations to levels that were not sig-
nificantly different from the sham-operated rats. However,
PTH concentrations were higher in rats treated with calcitriol
(284.1±44.0 pg ml1, Po0.001) and with paricalcitol
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Figure 1 | Kaplan-Meier survival curve in nephrectomized rats
(5/6 Nx) treated with vehicle (saline) (n¼ 8), calcitriol 80 ng kg1
i.p. (n¼ 11), paricalcitol 240 ng kg1 i.p. (n¼ 10), AMG 641
1.5 mg kg1 subcutaneously (n¼ 7), the combination calcitriol
80 ng kg1 and AMG 641 1.5 mg kg1 (n¼ 10), or the
combination paricalcitol 240 ng kg1 and AMG 641 1.5 mg kg1
(n¼ 10).
a: P<0.05 vs sham
b: P<0.05 vs 5/6 Nx+calcitriol
c: P<0.05 vs 5/6 Nx+vehicle
d: P<0.05 vs 5/6 Nx+paricalcitol
Sham 5/6 Nx
vehicle
5/6 Nx
calcitriol
5/6 Nx
AMG 641
5/6 Nx
paricalcitol
AMG 641
5/6 Nx
paricalcitol
5/6 Nx
calcitriol
AMG 641
Sham 5/6 Nx
vehicle
5/6 Nx
calcitriol
5/6 Nx
AMG 641
5/6 Nx
paricalcitol
AMG 641
5/6 Nx
paricalcitol
5/6 Nx
calcitriol
AMG 641
Sham 5/6 Nx
vehicle
5/6 Nx
calcitriol
5/6 Nx
AMG 641
5/6 Nx
paricalcitol
AMG 641
5/6 Nx
paricalcitol
5/6 Nx
calcitriol
AMG 641
a,b a
a
Pl
as
m
a 
Ca
2+
 
(m
M
)
a
a,b 
a
a
a,c
b,d
a
Pl
as
m
a 
P 
(m
g p
er 
10
0 m
l)
b,c 
a,b
0.90
1.00
1.10
1.20
1.30
1.40
4
8
12
16
20
24
100
200
300
400
500
a
a,c
b,c
a,c
Pl
as
m
a 
iP
TH
 (p
g m
l−1
)
b,c,d
b,c
Figure 2 | Blood biochemistry. Plasma levels of (a) ionized calcium,
(b) phosphorus, and (c) PTH in sham-operated rats (n¼ 7), or 5/6 Nx
rats treated for 14 days (qod) with vehicle (n¼ 18), calcitriol
(80 ng kg1) (n¼ 20), paricalcitol (240 ng kg1) (n¼ 12), AMG 641
1.5 mg kg1 (n¼ 16), calcitriolþAMG 641 (n¼ 15), or
paricalcitolþAMG 641 (n¼ 10).
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(191.1±41.5 pg ml1, P¼ 0.01) than in sham-operated
animals (Figure 2c).
The examination of the plasma biochemical parameters at
day 28 was limited by mortality in the vitamin D-treated
groups. Plasma creatinine in 5/6 Nx rats treated with vehicle
(1.10±0.06 mg per 100 ml), AMG 641(1.19±0.13 mg per
100 ml), and paricalcitol (1.74±0.24 mg per 100 ml) was
similar to the values recorded at day 14. However, rats treated
with calcitriol, alone (3.19±0.79 mg per 100 ml) or in
combination with AMG 641 (2.25±0.59 mg per 100 ml),
showed a further increase in creatinine. Plasma PTH
concentrations were increased in all treatment groups at
day 28 when compared with the values obtained at day 14.
Again, lower PTH levels were recorded in rats treated with
the combination of AMG 641 plus either calcitriol
(165.2±82.3 pg ml1) or paricalcitol (236.6±90.5 pg ml1).
When used alone, AMG 641 achieved a better control of
plasma PTH (433.5±150.1 pg ml1) than paricalcitol
(617.9±142 pg ml1) or calcitriol (1132.6±947.4 pg ml1).
Calcium and phosphorus values were similar to the values
observed at day 14. Since vitamin D-treated rats were
underrepresented, the differences between groups were less
evident.
Aortic and soft-tissue mineral content
Induction of renal failure and secondary HPT (5/6 Nx group)
resulted in a modest and nonsignificant increase in aortic Ca
content (3.5±0.3 vs 2.3±0.2 mg g1 of tissue in sham-
operated rats). Aortic Ca increased in rats treated with
calcitriol (15.5±1.5 mg g1 of tissue, Po0.001 vs 5/6 Nx).
Animals treated with AMG 641 had lower (Po0.05) aortic
calcium levels (3.0±0.3 mg g1 of tissue) than rats treated
with paricalcitol (6.4±1.3 mg g1 of tissue). Addition of
AMG 641 decreased aortic calcium in rats treated with
vitamin D analogs to 8.7±1.4 mg g1 (calcitriolþAMG 641)
and 3.2±0.7 mg g1 (paricalcitolþAMG 641) (Figure 3a).
Aortic Ca values recorded at day 28 were similar to those
recorded at day 14 (Figure 4a).
Aortic phosphorus content was increased in rats treated
with calcitriol (11.5±1.4 mg g1 of tissue, Po0.001), par-
icalcitol (5.3±1.7 mg g1 of tissue, Po0.01), and the
combination calcitriolþAMG 641 (6.6±1.9 mg g1 of
tissue, Po0.001) when compared with 5/6 Nx rats that did
not receive treatment (0.5±0.1 mg g1). Treatment with
AMG 641 did not increase aortic phosphorus, neither when
used alone (0.4±0.1 mg g1) nor in combination with
paricalcitol (0.8±1.7 mg g1). When compared with day
14, aortic phosphorus values were significantly (Po0.05)
increased in all groups at day 28, except in rats treated with
AMG 641 (0.2±0.1 mg g1 of tissue) (Figures 3b and 4b).
In situ aortic mineralization was examined by means of
the von Kossa staining method (Figure 5). No obvious
mineral deposits in the aorta (zero semiquantitative score)
were observed in either the sham-operated (not shown),
vehicle (Figure 5a), or AMG 641-treated 5/6 Nx groups
(Figure 5d). However, marked von Kossa staining (3.8±0.2
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Figure 3 | Aortic mineral content. (a) Calcium and (b) phosphorus
content of the aorta in sham-operated rats (n¼ 7), or 5/6 Nx rats
treated for 14 days (qod) with vehicle (n¼ 18), calcitriol (80 ng kg1)
(n¼ 20), paricalcitol (240 ng kg1) (n¼ 12), AMG 641 1.5 mg kg1
(n¼ 16), calcitriolþAMG 641 (n¼ 15), or paricalcitolþAMG 641
(n¼ 10).
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Figure 4 | Aortic mineral content. (a) Calcium and (b) phosphorus
content of the aorta in sham-operated rats (n¼ 6), or 5/6 Nx rats
treated for 28 days (qod) with vehicle (n¼ 8), calcitriol (80 ng kg1)
(n¼ 10), paricalcitol (240 ng kg1) (n¼ 9), AMG 641 1.5 mg kg1
(n¼ 7), calcitriolþAMG 641 (n¼ 10), or paricalcitolþAMG 641
(n¼ 10).
302 Kidney International (2008) 73, 300–307
o r i g i n a l a r t i c l e I Lopez et al.: Calcimimetic decreases extraosseous calcification
score) was detected in the aortic media of 5/6 Nx rats treated
with calcitriol alone (Figure 5b). Rats treated with paricalcitol
showed aortic mineralization to a lesser extent (2.4±0.3
score) compared with calcitriol (Figure 5c). The addition of
AMG 641 to the vitamin D treatment regimen reduced
mineralizations in calcitriol-treated rats (3±0.4 score)
(Figure 5e) and, in rats receiving the combination paricalci-
tolþAMG 641, prevented (0.4±0.2 score) the development
of aortic calcification (Figure 5f).
Calcification was also demonstrated in soft tissues by
histology (heart and remnant kidney) and measurement of
mineral content (lung and stomach). Severe calcification of
heart arteries and renal tubules and glomeruli was observed
in rats treated with calcitriol (Figure 6a and b). Rats treated
with paricalcitol alone did not show cardiac calcifications but
showed abundant calcium deposits in some renal tubules
(Figure 6e and f). Addition of AMG 641 significantly
decreased calcification in both calcitriol (Figure 6c and d)-
and paricalcitol (Figure 6g and h)-treated rats.
Measurements of tissue calcium and phosphorus content
in the stomach and in the lung at days 14 and 28 are shown in
Tables 1 and 2. Calcitriol-treated rats had a higher calcium
and phosphorus content in both stomach and lung than
vehicle-treated rats (Po0.05). Although the differences were
not statistically significant, rats treated with AMG 641 had
lower mineral content in the stomach and the lung.
Moreover, in general, addition of AMG 641 tended to reduce
the mineral organ content in rats treated with vitamin D
derivatives at 14 days.
DISCUSSION
In this study, in uremic rats with severe secondary HPT, the
calcimimetic AMG 641 was more effective in reducing serum
PTH levels and induced less extraskeletal calcifications than
calcitriol or paricalcitol. When used in combination with
paricalcitol, AMG 641 provided excellent control of second-
ary HPT without inducing significant calcifications and
prevented mortality associated with the use of vitamin D
derivatives.
Cardiovascular disease is the leading cause of mortality in
patients receiving dialysis.23 Management of patients receiv-
ing dialysis requires control of secondary HPT and associated
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Figure 5 | In situ aortic mineralization. Von Kossa stained sections
of the aorta in 5/6 Nx rats treated for 14 days (qod) with (a) vehicle,
(b) calcitriol (80 ng kg1), (c) paricalcitol (240 ng kg1), (d) AMG 641
1.5 mg kg1, (e) calcitriolþAMG 641, or (f) paricalcitolþAMG 641.
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Figure 6 | Von Kossa-stained sections of the heart and kidney from
rats treated with calcitriol (80 ng kg1, qod) showing severe
calcification of (a) heart arteries and (b) renal tubules and glomeruli.
Rats treated with paricalcitol alone (240 ng kg1, qod) did not show
(e) cardiac calcifications but showed abundant calcium deposits in
(f) some renal tubules. Addition of AMG 641 (1.5 mg kg1, qod)
significantly decreased calcification in both (c and d) calcitriol- and
(g and h) paricalcitol-treated rats. Original magnification¼  100.
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extraosseous calcification. Vitamin D derivatives, which
decrease the serum levels of PTH, are part of the traditional
treatment for secondary HPT. However, recent evidence
suggests that treatment with the vitamin D derivatives may be
associated with the development of VC in patients receiving
dialysis,15,22 and in animal-models of uremia,24,25 although
not all reports agree with this.26 The calcifying effects of
vitamin D may be related to elevations in blood calcium and
phosphorus, and it may also have a direct effect on
VSMC.12,14,15 To overcome the side effects of calcitriol on
serum calcium and phosphorus, vitamin D derivatives with
less reported calcemic actions, like paricalcitol, have been
developed.16,17
A different approach for treatment of secondary HPT in
dialysis patients is the use of calcimimetics, which increase
the sensitivity of the calcium-sensing receptor to extracellular
calcium, thereby suppressing PTH synthesis18 and secretion19
without inducing hypercalcemia.20,21 In a recent study, we
have shown that the calcimimetic R-568 reduced serum PTH
and calcium and phosphorus levels without causing aortic
and soft-tissue calcification, and attenuated the mineralizing
effect of calcitriol on vascular and extravascular tissue.22
Currently, there is little clinical evidence supporting a
positive effect of a pharmacologic intervention for secondary
HPT on patient survival. Based on results of a retrospective
analysis of an observational database, it has been suggested
that vitamin D may increase patient survival,27 although
additional evidence suggests that this may not be the case.28
In this trial, rats treated with either calcitriol or paricalcitol
demonstrated a significantly greater mortality than those
treated with AMG 641. It is difficult to compare human
retrospective studies (in which patients may be receiving
vitamin D replacement therapy to account for the lack of
production of endogenous calcitriol) with this prospective
study (in which calcitriol was administered to control
secondary HPT). Thus, it would be necessary to conduct
human trials to compare the influence of the different
treatments for secondary HPT on survival.
The reasons for the higher survival rate in the non-
vitamin D-treated rats, although they have not been fully
elucidated, may be related to the vitamin D-associated
reduction in renal function and increase in VC, or with a
calcimimetic-mediated positive effect on blood pressure29 or
renoprotection.30 When uremic survivors and non-survivors
were compared in this study, mineralization was found to be
more accentuated in non-survivors, aortic calcium (5.5±0.8
vs 11.5±0.6 mg g1 of tissue, Po0.001), aortic phosphorus
(6.7±1.7 vs 19.7±1.1 mg g1 of tissue, Po0.001), gastric
calcium (0.5±01 vs 1.6±0.3 mg g1 of tissue, Po0.001), and
gastric phosphorus (0.6±0.1 vs 1.8±0.3 mg g1 of tissue,
Table 1 | Mineral content (mg per g of tissue) of the stomach and lung after 14 days of treatment in sham-operated (Sham) rats
and 5/6 nephrectomized rats (5/6 Nx) treated on alternate days with vehicle (saline solution), calcitriol (80 ng kg1 i.p.),
paricalcitol (240 ng kg1 i.p.), the calcimimetic AMG 641 (1.5 mg kg1 s.c.), the combination calcitriol+AMG 641, or
paricalcitol+AMG 641
Stomach Lung
Calcium (mg g1) Phosphorus (mg g1) Calcium (mg g1) Phosphorus (mg g1)
Sham (n=7) 0.17±0.01 0.31±0.05 0.24±0.05 0.29±0.05
5/6 Nx+vehicle (n=18) 0.28±0.05 0.36±0.05 0.31±0.07 0.29±0.03
5/6 Nx+calcitriol (n=20) 1.78±0.34a 1.50±0.37a 1.45±0.46a 1.26±0.36a
5/6 Nx+paricalcitol (n=11) 0.70±0.21 0.96±0.38 0.78±0.36 0.63±0.34
5/6 Nx+AMG 641 (n=16) 0.09±0.02 0.25±0.02 0.28±0.11 0.20±0.02
5/6 Nx+calcitriol+AMG 641 (n=15) 1.33±0.26a 1.18±0.36a 1.14±0.26a 0.89±0.34
5/6 Nx+paricalcitol+AMG 641 (n=9) 0.65±0.24 0.42±0.15 0.49±0.18 0.53±0.27
i.p., intraperitoneally; s.c., subcutaneously.
aPo0.05 vs 5/6 Nx+vehicle.
Table 2 | Mineral content (mg per g of tissue) of the stomach and lung after 28 days of treatment in sham-operated (Sham) rats
and 5/6 nephrectomized rats (5/6 Nx) treated on alternate days with vehicle (saline solution), calcitriol (80 ng kg1 i.p.),
paricalcitol (240 ng kg1 i.p.), AMG 641 (1.5 mg kg1 s.c.), the combination calcitriol+AMG 641, or paricalcitol+AMG 641
Stomach Lung
Calcium (mg g1) Phosphorus (mg g1) Calcium (mg g1) Phosphorus (mg g1)
Sham (n=6) 0.14±0.01 0.35±0.05 0.20±0.05 0.27±0.05
5/6 Nx+vehicle (n=8) 0.13±0.02 0.33±0.04 0.19±0.08 0.28±0.06
5/6 Nx+calcitriol (n=10) 2.18±0.33a 2.35±0.39a 0.63±0.39a 0.59±0.16a
5/6 Nx+paricalcitol (n=9) 0.87±0.25 0.96±0.20 0.17±0.06 0.14±0.03
5/6 Nx+AMG 641 (n=7) 0.25±0.09 0.39±0.03 0.15±0.04 0.19±.0.04
5/6 Nx+calcitriol+AMG 641 (n=10) 0.89±0.35 1.07±0.26 0.12±0.04 0.18±0.04
5/6 Nx+paricalcitol+AMG 641 (n=10) 0.25±0.06 0.54±0.07 0.19±0.02 0.18±0.02
i.p., intraperitoneally; s.c., subcutaneously.
aPo0.05 vs 5/6 Nx+vehicle.
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Po0.001). Thus, mineral deposition and its associated
cardiovascular consequences seem to play a pivotal role as
the cause of death. In addition, a significant decrease in body
weight (202±10 vs 251±16 g, Po0.05) was also detected in
the rats that died. Of interest, in this study, while treatment
with a calcimimetic did not improve renal function when
used alone, it did abrogate the calcitriol- and paricalcitol-
induced increases in serum creatinine. The renoprotective
effect of AMG 641 is in agreement with previous studies with
calcimimetics R-568 and R-467, which have been shown to
attenuate vitamin D- and furosemide-mediated nephrocalci-
nosis in rats.22,31
Moreover, treatment with the calcimimetic reduced the
extraosseus calcifications observed with both calcitriol and
paricalcitol. Recent evidence has suggested that uremia-
associated VC results from a myriad of changes in the
expression of both mediators and inhibitors of calcification,
and the transformation of the vascular smooth muscle cells to
a more osteo/chondrocytic cell type. Of particular interest to
the authors is in vitro evidence has shown that both
paricalcitol and calcitriol induce significant amounts of
mineralization in vascular smooth muscle cells, while AMG
641 does not.15 Thus, vitamin D derivatives seem to have
direct procalcific effects beyond their influence on parameters
of mineral metabolism. In previous studies, we have shown
that the anticalcifying effect of calcimimetics is due, in part,
to the reductions in the serum Ca P product.22 This
mechanism may also be responsible for the decreased
calcification found in this study since all groups treated with
AMG 641 had lower Ca and, particularly, lower P. However,
other mechanisms may also be implicated since VSMC
express calcium-sensing receptor32 and may directly respond
to calcimimetics.
A frequent critique to the in vivo studies of vitamin D-
induced VC is that the doses of vitamin D derivatives used
are very high. In this study, the doses of calcitriol and
paricalcitol cannot be considered too high since they did not
achieve control of secondary HPT (as demonstrated by the
elevated PTH levels in the calcitriol- and paricalcitol-treated
rats). In fact, to achieve complete control of secondary HPT
using only vitamin D derivatives, higher doses of calcitriol or
paricalcitol would have been necessary, potentially resulting
in more severe calcifications. However, it should also be
noted that the relationship between calcitriol dose and degree
of PTH reduction is not perfectly linear. When high doses of
calcitriol are administered to rats fed a high phosphorus diet,
plasma P may increase to a point in which it is not possible to
suppress PTH secretion. Thus, even though it may seem
paradoxical, a high dosage of calcitriol can result in an
increase in PTH secretion in uremic rats, as demonstrated by
recent studies.25 In addition, very high doses of calcitriol
cause massive calcifications,24,25 which may not prevented by
calcimimetic treatment.24
In contrast with a previous study in which R-568 was
used,22 the dosing regime of AMG 641 was similar to the
vitamin D analogs (every 48 h) thus excluding any influence
of the more frequent dosing required with R-568 on the
anticalcifying effects of the calcimimetic.
In conclusion, this study shows that, when administered
to uremic rats, the calcimimetic AMG 641 effectively reduces
PTH without inducing extraskeletal calcifications under
conditions in which the vitamin D derivatives did. Calcitriol
and paricalcitol are both less effective than AMG 641 in
controlling secondary HPT and in avoiding VCs. When used
in combination with paricalcitol, AMG 641 provided
excellent control of secondary HPT and diminished par-
icalcitol-mediated VC.
MATERIALS AND METHODS
Animals
Male Wistar rats weighing 250 g were purchased from the Animal
Breeding Facility of the University of Cordoba (Spain). Rats were
housed with a 12/12 h light/dark cycle and given ad libitum access to
normal diet (calcium: 0.9%, phosphorus: 0.6%, vitamin D:
500 IU kg1). The experimental protocols were reviewed and
approved by the Ethics Committee for Animal Research of the
University of Cordoba, and all animals received humane care in
compliance with the Principles of Laboratory Animal Care
formulated by the National Society for Medical Research, and the
Guide for the Care and Use of Laboratory Animals prepared by the
National Academy of Science.
5/6 Nephrectomy
The uremia in the rodent model of CKD used in these studies was
induced by 5/6 nephrectomy (5/6 Nx), a two-step procedure that
reduces the original functional renal mass by 5/6. In the first step,
animals were anesthetized using xylazine (5 mg kg1, intraperitone-
ally (i.p.)) and ketamine (80 mg kg1, i.p.), an 8-mm incision was
made on the left medio-lateral surface of the abdomen, and the left
kidney was exposed. The two renal poles were tightly ligated and
ablated, thus leaving 1/3 of the original renal mass. After 1 week of
recovery, the animal was reanesthetized and an 8-mm incision was
made on the right medio-lateral surface of the abdomen. The right
kidney was exposed and unencapsulated, the renal pedicle clamped
and ligated, and the kidney was removed. Sham-operated animals
underwent the same procedures without renal manipulation.
Experimental design
The experimental schedule is shown in Figure 7. After the second
surgery, the diet was changed to lower calcium (0.6%) and increased
phosphorus (1.2%) content. The rats were randomly assigned
(based on the normal distribution of baseline body weights) into
seven experimental groups: sham-operated (n¼ 13) (used as a
control), 5/6 Nxþ vehicle (saline) (n¼ 26), 5/6 Nxþ calcitriol
80 ng kg1 i.p. (Calcijex, Abbot, Madrid, Spain) (n¼ 31), 5/6
Nxþ paricalcitol 240 ng kg1 i.p. (Zemplar, Abbot, Madrid, Spain)
(n¼ 22), 5/6 NxþAMG 641 1.5 mg kg1 subcutaneously (Amgen,
Thousand Oaks, CA, USA) (n¼ 23), 5/6 Nxþ combination
calcitriol 80 ng kg1 and AMG 641 1.5 mg kg1 (n¼ 25) dosed as
above, or 5/6 Nxþ combination paricalcitol 240 ng kg1 and AMG
641 1.5 mg kg1 (n¼ 20) dosed as above. All treatments were
administered every 48 h. Preliminary experiments with AMG 641 in
rats indicated that the drug maintained its pharmacological effect
through a 48-h period when administered either i.p. or subcuta-
neously (data not shown). The subcutaneous route was chosen to
avoid any potential drug interference between AMG 641 and
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vitamin D analogs (administered i.p.) in rats receiving both drugs.
At day 14, 2/3 of the animals were killed, sham-operated rats
(n¼ 7), 5/6 Nxþ vehicle (n¼ 18), 5/6 Nxþ calcitriol (n¼ 20), 5/6
Nxþ paricalcitol (n¼ 12), 5/6 NxþAMG 641 (n¼ 16), 5/6
Nxþ calcitriolþAMG 641 (n¼ 15), and 5/6 Nxþ paricalci-
tolþAMG 641 (n¼ 10). Treatments were maintained for the
remaining animals for 28 days. At day 28, all surviving rats were
killed by aortic puncture and exsanguination under general
anesthesia (i.p. sodium thiopental). Euthanasia was performed
24 h after receiving the last dose of study drugs. Following killing,
the thoracic aorta, the heart, the lungs, the stomach, and the
remnant kidney were dissected.
In the 28-day experiments, some rats died before the completion
of the study. Deaths were recorded to assess the difference in survival
rate between treatments. In dead rats, blood samples could not be
obtained; however, the aortas and organs from these rats were
retrieved shortly after death and were used for assessment of
calcification.
Assessment of vascular and soft-tissue calcification
Vascular and soft-tissue calcification was studied by histology and by
measuring the tissue calcium and phosphorus content. To avoid
sampling bias, the same section of the aorta from every animal was
selected for each study: cranial third for histology and middle third
for calcium and phosphorus quantification. The cranial part of the
thoracic aorta, the heart, and the remnant kidney were fixed in 10%
buffered formalin and subsequently sectioned and stained for
mineralization by the von Kossa method. The extent of calcification
(von Kossa staining) was blindly evaluated by three independent
observers using a semiquantitave score (range 0–4). The middle part
of the aorta was demineralized in 10% formic acid, and the arterial
tissue calcium and phosphorous content was measured in the
supernatant according to the method described by Price et al.33
Based on the results of a previous study in which significant gastric
and pulmonary calcifications were found in this model of uremia,22
the stomach and the lung were chosen for quantification of tissue
mineral content. The stomach and the left lung from each animal
were placed into separate 30 ml tubes. Twenty milliliter of 150 mM
HCl was added to each tube. The tubes were mixed by inversion for
24 h at room temperature and calcium and phosphorus were
measured in the acid extract.34
Blood chemistries
Blood for chemistry analyses was obtained from the abdominal
aorta at the time of killing. Blood for measurements of ionized
calcium levels was collected in heparinized syringes and immediately
analyzed using a Ciba-Corning 634 ISE Ca2þ /pH Analyzer (Ciba-
Corning, Essex, UK). Afterward, plasma was separated by centrifu-
gation and stored at 201C until assayed. PTH levels were
quantified according to the vendor’s instructions using a rat
PTH(1–34) immunoradiometric assay kit (Immunotopics, San
Clemente, CA, USA). Plasma creatinine, phosphorous, and total
calcium were measured by spectrophotometry (Sigma Diagnostics,
St Louis, MO, USA).
Statistics
Values are expressed as the mean±s.e. The difference between
means for two different groups was determined by t-test; the
difference between means for three or more groups was assessed by
analysis of variance followed by an least significant difference post
hoc test. Po0.05 was considered significant. Survival was studied by
Kaplan–Meier curves followed by log-rank tests.
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